Immunotherapy for Rheumatoid Arthritis-Associated Coronary Artery Disease

0
0
0

Immunotherapy for Rheumatoid Arthritis-Associated Coronary Artery Disease: Promise and Future

Introduction
Rheumatoid arthritis (RA) is a chronic immune-mediated inflammatory disease with a global prevalence of 0.24% and an annual incidence of approximately 40 per 100,000 individuals. Beyond its hallmark articular manifestations, RA significantly impacts extra-articular organs, particularly the cardiovascular system. Coronary artery disease (CAD) is the leading cause of mortality in RA patients, accounting for nearly half of all deaths. The risk of cardiovascular disease (CVD) in RA patients is 50% higher in incidence and 60% higher in mortality compared to the general population. This elevated risk arises from a combination of shared risk factors, RA-driven metabolic disturbances, and the systemic inflammatory cascade that accelerates atherosclerosis and coronary microvascular dysfunction.

RA and CAD: Pathophysiological Links
RA is recognized as an independent risk factor for CAD. Autopsy studies reveal a higher prevalence of unstable coronary plaques and intensified local inflammation in RA patients. The incidence of myocardial infarction (MI) and recurrent acute coronary syndrome (ACS) is significantly increased, with coronary plaques developing earlier and progressing more aggressively. Notably, newly diagnosed RA patients do not exhibit a higher prevalence of CAD than the general population before symptom onset, suggesting that RA-specific mechanisms drive CAD progression post-diagnosis.

Shared and RA-Specific Risk Factors
RA and CAD share common risk factors such as smoking and genetic susceptibility (e.g., HLA-DR4 phenotype). However, RA uniquely exacerbates traditional CAD risk factors through chronic inflammation:

  1. Hypertension: Pro-inflammatory cytokines like C-reactive protein (CRP) upregulate angiotensin type-1 receptors and reduce nitric oxide (NO) production, impairing vasodilation.
  2. Dyslipidemia: Paradoxically, RA patients exhibit lower total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels due to inflammation-induced lipid metabolism alterations. Treatments targeting IL-6 (e.g., tocilizumab) or Janus kinase (JAK) inhibitors normalize lipid profiles but transiently elevate LDL-C and TC.
  3. Insulin Resistance: Tumor necrosis factor-α (TNF-α) and IL-6 impair insulin signaling, while therapies like TNF inhibitors improve glucose metabolism.

Inflammatory Mechanisms Driving CAD in RA
The inflammatory cascade in RA directly promotes endothelial dysfunction and immune dysregulation, fostering atherosclerosis and microvascular impairment. Key pathways include:

  1. Cytokine-Mediated Damage:
    • IL-6, IL-1β, and TNF-α reduce endothelial NO synthase activity, increase reactive oxygen species (ROS), and induce pro-apoptotic proteins (Bim, Bax), destabilizing plaques.
    • Elevated CRP correlates with CAD risk but serves as a marker rather than a direct effector.
  2. Immune Cell Activation:
    • CD4+/CD8+ T cells and CD14highCD16+ monocytes are enriched in RA patients with high coronary artery calcification (CAC).
    • Macrophages in RA-CAD exhibit metabolic defects (e.g., GSK3β deactivation), driving oxidative stress and tissue destruction.
  3. Autoantibodies:
    • Anti-citrullinated protein antibodies (ACPAs) cross-react with vascular proteins, enhancing LDL uptake by foam cells and promoting neutrophil extracellular trap (NET) formation.
    • Antibodies against carbamylated proteins and oxidized LDL further amplify vascular inflammation.
  4. Complement Activation:
    • Perivascular adipose tissue in RA synthesizes complement proteins (e.g., pentraxin 3), which exacerbate endothelial injury and monocyte infiltration.

Therapeutic Strategies for RA-Associated CAD
Current management focuses on controlling inflammation while addressing traditional CAD risk factors. The European League Against Rheumatism (EULAR) emphasizes tight disease activity control to mitigate CVD risk.

1. Conventional Synthetic DMARDs (csDMARDs)

  • Methotrexate (MTX): Reduces cardiovascular events (CVEs) and MI risk by 18% in meta-analyses. However, the CIRT trial showed no benefit in stable atherosclerosis patients without active inflammation.
  • Hydroxychloroquine (HCQ): Lowers LDL-C, increases HDL-C, and reduces diabetes incidence. The ongoing OXI trial evaluates its role in post-MI secondary prevention.
  • Sulfasalazine and Leflunomide: Mixed evidence on CVD outcomes, with sulfasalazine showing endothelial benefits in stable CAD.

2. Biologic DMARDs (bDMARDs)

  • TNF Inhibitors (e.g., infliximab, etanercept): Reduce MI risk by 40% compared to csDMARDs. Good responders (EULAR criteria) achieve ACS risk comparable to the general population.
  • IL-1 Inhibition (e.g., canakinumab, anakinra): The CANTOS trial demonstrated a 15% reduction in recurrent CVEs with canakinumab (150 mg every 3 months) in post-MI patients with elevated hsCRP. Anakinra improves coronary flow reserve and left ventricular function.
  • IL-6 Receptor Inhibition (e.g., tocilizumab): Improves endothelial function but increases LDL-C and TC. No increased MACE risk compared to TNF inhibitors.
  • Rituximab (anti-CD20): Depletes B cells, reduces carotid intima-media thickness, and enhances macrovascular reactivity.

3. Targeted Synthetic DMARDs (tsDMARDs)

  • JAK Inhibitors (e.g., tofacitinib, baricitinib): Elevate LDL-C and HDL-C but show neutral effects on cardiovascular outcomes in RA trials.

4. NSAIDs and Glucocorticoids

  • NSAIDs: Cyclooxygenase-2 inhibitors (COX-2i) like celecoxib reduce CAD risk short-term but increase it beyond four years. Naproxen is preferred for its safer profile.
  • Glucocorticoids: Dose-dependent increases in CVEs, heart failure, and mortality. Doses >8 mg/day prednisone-equivalent are particularly harmful.

Clinical Management Optimization

  1. Risk Stratification: No validated RA-specific CAD risk score exists, but tools like QRISK3 incorporate inflammation markers.
  2. Treatment Response Monitoring: Drug efficacy varies; TNF inhibitor responders show near-normal ACS risk, while non-responders face double the risk.
  3. Combination Therapy: Triple therapy (MTX + sulfasalazine + HCQ) improves lipid profiles compared to MTX monotherapy or TNF inhibitors.

Future Directions

  1. Precision Medicine: Integrate multi-omics data (genomic, proteomic) to predict drug responses and tailor therapies.
  2. Novel Targets: Explore S100 proteins (A8/A9), NKT cells, and complement regulators (e.g., C5a inhibitors).
  3. Immune Modulation: Combine biologics with statins or PCSK9 inhibitors to offset metabolic side effects.
  4. Extended Indications: Test anti-inflammatory therapies in subclinical atherosclerosis or ACS, leveraging RA as a model of inflammatory CAD.

Conclusion
RA-associated CAD is driven by a synergistic interplay of chronic inflammation, metabolic dysregulation, and immune dysfunction. Emerging biologic therapies, particularly IL-1 and IL-6 inhibitors, show promise in reducing cardiovascular risk while controlling articular disease. Future research must prioritize personalized approaches, long-term safety monitoring, and novel combinatorial strategies to address this complex comorbidity.

doi.org/10.1097/CM9.0000000000000530

Was this helpful?

0 / 0